NVCR Earnings Date: Feb 25, 2027 (Estimated) — Novocure Ltd
NASDAQ · Healthcare · Medical Devices
Updated
When is NVCR's next earnings date?
Novocure Ltd (NVCR) is expected to report Q4 2026 earnings on Thursday, February 25, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.24 on revenue of $186.2M.
How did NVCR do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), Novocure Ltd posted EPS of -$0.09 versus the -$0.23 estimate, a beat of 61.7%. Revenue was $193.4M against a $182.3M estimate. The stock's 1-day post-earnings move was -7.5%.
How much does NVCR stock move after earnings?
NVCR beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 14.7% (up or down) in the day after earnings.
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
🤖 AI Earnings Analysis
NovoCure’s Verastem collaboration will test Tumor Treating Fields alongside a KRAS G12D inhibitor in pancreatic cancer, a promising clinical catalyst. Q3 revenue beat estimates at $193M, but operating losses remained $36M.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | -0.23 | -0.09 | +61.68% | $193.4M | ✅ Beat | -7.48% | — | — |
| 2026-07-23 | Q2 2026 | -0.33 | -0.13 | +60.61% | $183.6M | ✅ Beat | +28.39% | -2.38% | +14.13% |
| 2026-04-30 | Q1 2026 | -0.49 | -0.62 | -26.53% | $174.1M | ❌ Miss | +27.49% | +38.26% | +42.83% |
| 2026-02-26 | Q4 2025 | -0.41 | -0.22 | +46.34% | $174.3M | ✅ Beat | -8.27% | -10.47% | -21.55% |
| 2025-10-30 | Q3 2025 | -0.42 | -0.33 | +21.43% | $167.2M | ✅ Beat | -4.90% | -13.87% | -4.97% |
| 2025-07-24 | Q2 2025 | -0.39 | -0.36 | +7.69% | $158.8M | ✅ Beat | -24.05% | -33.56% | -27.86% |
| 2025-04-24 | Q1 2025 | -0.46 | -0.31 | +32.61% | $155.0M | ✅ Beat | +4.39% | +2.08% | +1.91% |
| 2025-02-27 | Q4 2024 | -0.34 | -0.61 | -79.41% | $161.3M | ❌ Miss | -12.43% | -12.80% | -13.62% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q3 FY26 · $251.6M total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 44.5% | $111.9M | +15.8% | $93.2M | $94.3M | $96.6M | $101.6M |
| International Markets | 30.6% | $77.0M | +18.5% | $57.2M | $60.0M | $65.0M | $68.1M |
| GERMANY | 9.9% | $24.9M | +23.0% | $18.7M | $19.1M | $20.3M | $21.3M |
| FRANCE | 7.4% | $18.7M | -4.6% | $17.9M | $18.4M | $19.6M | $20.3M |
| JAPAN | 5.8% | $14.5M | +54.7% | $8.7M | $9.5M | $9.4M | $10.2M |
| CHINA | 1.8% | $4.5M | -19.8% | $4.6M | $4.6M | $5.6M | $4.6M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.